ITM-91 by ITM Isotope Technologies Munich for Metastatic Colorectal Cancer: Likelihood of Approval

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Metastatic Colorectal Cancer.

Theabrownin from dark tea may have the potential to treat insulin resistance

The effects of theabrownin (TB) from dark tea treatment on insulin resistance (IR).

September 8, 2023

Modernizing Healthcare Communications with Cloud-Based Faxing

Tim Armstrong, Head of Product Management, Retarus Healthcare organizations recognize that modern communication systems are crucial to enhancing operational efficiency and securing sensitive patient information.

December 19, 2024

Timing of nocturnal hot flashes may impact heart disease risk

Nocturnal hot flashes are disruptive regardless of when they occur during the night. A new study suggests that more hot flashes occur during the second

September 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.